Impact_of_autologous_bone_marrow_infusion_on_hematopoietic_recovery_after_high-dose_cyclophosphamide,_etoposide,_and_cisplatin._Because_of_potential_tumor_contamination_and_inadequacy_of_current_purging_technique_of_bone_marrow_in_patients_with_solid_tumors,_we_investigated_an_alternative_approach_to_high-dose_therapy_without_autologous_bone_marrow_(ABM)_infusion._Three_levels_of_nonmyeloablative_doses_of_cyclophosphamide_4.5_to_5.25_g/m2,_etoposide_750_to_1,200_mg/m2,_and_cisplatin_120_to_165_mg/m2_(CVP)_were_administered_to_patients_with_metastatic_solid_tumors._Patients_were_randomized_to_ABM_(n_=_46)_or_no-ABM_(NABM)_(n_=_46)_infusion_after_CVP_to_study_the_impact_of_ABM_on_hematopoietic_recovery,_morbidity,_and_mortality._All_patients_had_ABM_harvested,_underwent_conventional_chemotherapy,_and_then_received_CVP._Seventy-three_patients_received_two_courses_of_similar_doses._The_following_were_the_median_days_to_absolute_neutrophil_count_(ANC)_of_0.1_x_10(9)/L:_for_the_ABM_arm,_19,_21,_and_19_and_for_the_NABM_arm,_23,_20,_and_21_at_levels_1,_2,_and_3,_respectively,_during_course_1_(P_=_.01,_.80,_and_.01,_respectively)._During_course_2,_ANCs_to_0.1_x_10(9)/L_and_0.5_x_10(9)/L_were_attained_significantly_faster_at_levels_1_and_3_in_the_ABM_arm._ANC_to_1.0_x_10(9)/L_was_comparable_in_both_arms._Incidence_of_infection_and_duration_of_fever_were_similar_in_both_arms._Although_mortality_and_the_incidence_of_delayed_hematopoietic_recovery_were_more_frequent_in_the_NABM_arm,_this_was_not_statistically_significant._Platelet_recovery_was_consistently_prolonged_in_course_2_in_both_arms,_with_demonstrable_benefit_of_ABM_in_course_2_when_dose_levels_were_collectively_considered._We_conclude_that_(1)_ABM_enhanced_recovery_of_ANC_to_0.1_x_10(9)/L;_(2)_ABM_did_not_decrease_the_incidence_of_infections_and_the_duration_of_fever;_and_(3)_CVP_can_be_safely_given_without_ABM_to_carefully_selected_patients.